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PGI12
GASTROINTESTINAL COMPLICATIONS INDUCED BY NON-
STERIODAL ANTI-INFLAMMATORY DRUGS (NSAID):
EPIDEMIOLOGICAL EXTRAPOLATION FOR EUROPE AND
ECONOMIC CONSIDERATIONS
Sterzel A1, Grass U2, Berger K3, Plesnila-Frank C3
1Altana Pharma AG, Konstanz, Germany, 2Altana Pharma Deutschland
GmbH, Konstanz, Germany, 3MERG-Medical Economics Research
Group, Munich, Germany
OBJECTIVES: To calculate the dimension of NSAID induced GI
complications in Europe because few epidemiologic data exist.
To ﬁnd evidence of treatment patterns and analyse data on the
economic burden of NSAID induced GI complications. To assess
the economic beneﬁt of ulcer prophylaxis with proton pump
inhibitors (PPI). METHODS: Pub Med and Cochrane Library
literature research was conducted with deﬁned MESH terms. An
epidemological extrapolation was done to estimate hospitalisa-
tion and death cases due to NSAID use in Europe, limited to
rheumatoid arthritis (RA) and osteoarthritis (OA) patients. Eco-
nomic beneﬁt of ulcer prophylaxis was examined on the basis 
of international cost of illness and cost effectiveness studies.
RESULTS: Eighty-three studies were analysed. Approximately 3
million patients with RA and 17.3 million patients with OA were
calculated for Europe. Potential incidence of hospitalisation due
to NSAID use was 157933 patients annually with estimated
25222 cases of death. In the UK, total costs for inpatient stay
and treatment of complications were about 367.5 million Euros
per year. Data from The Netherlands showed that 14% of the
costs of all GI complications were due to NSAID use. Across
Europe, co-medication studies are rare; in France, co-medication
was prescribed in 29.5%, in Spain in 41.6%, and in The Nether-
lands in 43% of NSAID users. Indirect costs (e.g. loss of pro-
ductivity) ranged from 20–50% of total costs. CONCLUSION:
Compared to our epidemiological extrapolation, much higher
hospitalisation and death rates in Europe must be expected
because of the wide range of NSAID indications. A lack of out-
patient data limits a differentiated calculation of costs for NSAID
induced complications. Although guidelines for ulcer prophy-
laxis do exist in many European countries, daily routine shows
an inconsequent application of gastro protective agents. Given
the calculated prevalences, prophylactic ulcer care with PPI
should receive more attention in Europe.
PGI13
ECONOMIC EVALUATION OF THE ARTIFICIAL LIVER
SUPPORT SYSTEM MARS IN PATIENTS WITH ACUTE-ON-
CHRONIC LIVER FAILURE—FINAL RESULTS OF A CLINICAL
COHORT TRIAL
Hessel FP
University of Duisburg-Essen, Essen, Germany
OBJECTIVES: Acute-on-chronic liver failure (ACLF) is a life
threatening acute decompensation of a pre-existing chronic liver
disease. The artiﬁcial liver support system MARS is a new emerg-
ing therapeutic option for treatment of ACLF. The medical efﬁ-
cacy of MARS has been demonstrated in ﬁrst clinical studies.
Objective of this study was to determine survival rates, quality
of life, direct medical costs and cost-effectiveness. METHODS:
In a clinical cohort trial with a prospective follow-up of 3 years
and modelling of cost and survival for the remaining lifetime 62
consecutively included ACLF-patients treated with MARS were
compared to 87 controls. Survival, health-related quality of life
as well as direct medical costs for in- and outpatient treatment
from a health care system perspective were determined and by
bootstrapping the incremental costs per life year respectively
QALY gained were estimated. RESULTS: There were no signif-
icant baseline differences between the two groups. Patients
treated with MARS had a highly signiﬁcant better survival
(Logrank) with a mean outcome gain of 0.66 years, but boot-
strap analysis showed broad conﬁdence intervals (−0.12 to 1.46).
The average initial intervention costs for MARS were €14,600
per patient treated. Incremental direct medical costs were
€19,946 per patient treated with MARS (CI: 13,308 to 25,429).
The mean costs per life-year gained were €29,985, costs per
QALY were €43,040. In total, 34% of the bootstrap sample were
higher than €50,000 per QALY. CONCLUSIONS: The results of
the ﬁrst economic evaluation study of MARS based on empiri-
cal patient data are presented. Although high initial treatment
costs for MARS occur the signiﬁcantly better survival led to rea-
sonable costs per live year respectively QALY gained. But boot-
strap analysis of CER showed a probability of 34% to be higher
than 50,000€ per QALY gained. Further randomized controlled
trials investigating the medical efﬁcacy and the cost-effectiveness
are recommended.
PGI14
COMPARATIVE EFFICACY OF PARIET (RABEPRAZOLE):
LESSONS FROM CLAIMS DATA
Glass JR1, Rocchi A2, Lelorier J3
1Janssen-Ortho Inc,Toronto, ON, Canada, 2Axia Research, Hamilton,
ON, Canada, 3Universite de Montreal, Montreal, QC, Canada
OBJECTIVES: Pariet (rabeprazole) was introduced at a sub-
stantial price discount to existing, branded proton pump
inhibitors (PPIs) in Canada. Therefore, there may have been a
perception of comparative reduced efﬁcacy with Pariet, in part
because Pariet is generally dosed at two tablets daily, compared
to one unit daily for other PPIs. The objective was to conduct
individual claims data descriptive analyses to identify differences
in patterns of use indicative of reduced efﬁcacy or selection of
patients. METHODS: Individual claims data were obtained for
Ontario, Canada. PPI claims were followed backward in time to
determine if the patient had received a different PPI, an H2
antagonist or neither therapy previously (minimum time period,
twelve months). This could suggest selection bias for naïve
patients versus treatment-experienced patients. PPI claims were
followed forward in time to determine if there were subsequent
claims for a different PPI, an H2 antagonist, or neither. This
proxy measure was interpreted as a lack of efﬁcacy requiring
therapy switches. RESULTS: Pariet users were equally likely as
other PPI users to have had no claims for another PPI or H2 in
the previous twelve months (74% PPI market overall, 70%
Pariet). The proporton of patients who subsequently switched
therapy increased as the duration of follow-up increased.
Overall, Pariet users were most likely to have no subsequent
claims for another PPI or an H2 antagonist compared to other
PPIs (59% overall market, 71% Pariet users). CONCLUSION:
Claims data do not support that Pariet has different efﬁcacy from
other PPIs or is used differently.
PGI15
HEALTH-STATE UTILITIES IN LIVER DISEASE: A SYSTEMATIC
REVIEW AND META-ANALYSIS
McLernon DJ, Dillon JF, Donnan PT
University of Dundee, Dundee, UK
OBJECTIVES: Health-state utilities are essential for cost-effec-
tiveness analysis, and few estimates exist for liver disease in the
literature. Our aim was to conduct a systematic review of health-
state utilities in liver disease, and to estimate utilities for various
liver disease states for a large UK Department of Health study.
METHODS: Articles were included in the systematic review if
health-state utility tools were used to estimate utility or if they
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were estimated by expert opinion. If two or more studies esti-
mated utility for a similar disease state then a meta-analysis was
carried out to pool the variance weighted mean estimates.
RESULTS: Twenty-eight studies measured utilities of liver dis-
eases or disease states. Only nine of these studies were eligible
for meta-analysis for four health states in chronic liver disease
patients (compensated cirrhosis, decompensated cirrhosis, pre-
liver transplant and post-liver transplant) and three in Hepatitis
C patients (compensated cirrhosis, decompensated cirrhosis and
post-liver transplant). The pooled mean estimates in chronic liver
disease and hepatitis C patients with compensated cirrhosis were
0.87 (95% CI 0.62 to 1.12) and 0.83 (95% CI 0.68 to 0.99)
respectively. For decompensated cirrhosis they were 0.68 (95%
CI 0.40 to 0.95) and 0.73 (95% CI 0.50 to 0.97). For post-liver
transplant, the estimates were 0.70 (95% CI 0.40 to 1.01) and
0.76 (95% CI 0.52 to 1.01) respectively. Pre-liver transplant
patients with chronic liver disease had a utility estimate of 0.57
(95% CI 0.28 to 0.87). CONCLUSIONS: We have estimated
summaries of patient utilities for the major states of chronic liver
disease and hepatitis C, and created a valuable liver disease-
based utility resource for researchers and policy makers.
PGI16
ARE ADULTS MORE AVERSE TO TREATMENT RISKS FOR THEIR
CHILDREN THAN THEY ARE FOR THEMSELVES?
Johnson FR1, Ozdemir S1, Mansﬁeld C1, Hass SL2,White TJ2
1RTI International, Research Triangle Park, NC, USA, 2Elan
Pharmaceuticals Inc, San Diego, CA, USA
OBJECTIVE: Compare maximum acceptable risk (MAR) of
treatment-related serious adverse events (SAE) between adult
Crohn’s disease (CD) patients and parents of children with CD.
Information on beneﬁt-risk tradeoffs may aid clinicians and reg-
ulatory agencies in their decision-making. METHODS: An on-
line panel of adult CD patients and parents of children with CD
completed a series of choice-format conjoint tradeoff tasks. The
treatment attributes included daily symptom severity and activ-
ity limitations, the potential for serious disease complications,
the time between ﬂare-ups, oral steroid use, and varying levels
of three SAE mortality risks: serious infection, progressive mul-
tifocal leukoencephalopathy (PML) and lymphoma. The annual
MAR was calculated for 15 SAE-clinical beneﬁt combinations (3
SAEs X 5 levels of clinical improvement from a severe or mod-
erate CD state). RESULTS: A total of 357 adult patients and 105
parents completed the survey. Improvements in daily symptom
severity were the most important factor in treatment preferences.
Higher MAR (greater risk acceptance) was observed for trade-
off tasks involving higher levels of clinical beneﬁt. Compared to
adult patients, parents were willing to accept a greater SAE risk
for alleviation of severe CD symptoms (for 7 of 9 SAE vs. clin-
ical beneﬁt combinations), but were less willing to accept SAE
risk for improvement of moderate CD symptoms (for 6 of 6 com-
binations). CONCLUSIONS: Medical interventions carry risks
of adverse outcomes that must be evaluated against their clini-
cal beneﬁts. Adult patients and parents of children with CD indi-
cated they are willing to accept deﬁned mortality risks in
exchange for clinical efﬁcacy. While parents were more willing
to accept higher SAE risks for improvement of severe CD symp-
toms, patients were willing to accept higher risks for improve-
ment of moderate CD symptoms.
PGI17
DEPICTION OF GASTROESOPHAGEAL REFLUX DISEASE
(GERD) PREVALENCE IN PRIMARY CARE IN GREECE
Papatheodoridis G1, Pangali M2, Papageorgiou M2,
Christodoulopoulou A2
1Ippokration General Hospital, Athens, Greece, 2AstraZeneca SA,
Athens, Greece
OBJECTIVES: GERD is a frequent condition among the general
population, which is not often properly diagnosed or treated.
The study aimed to depict the prevalence of GERD within a
primary care setting, assess symptoms severity and frequency in
GERD patients, and to examine the association between GERD
and aspirin/NSAIDs use. METHODS: A total of 2878 individu-
als (M/F: 1411/1467, mean age 55, 19 ± 14,5 years, BMI 26, 7
± 3, 9 Kg/m2) visiting 300 Primary Care Practitioners (PCP)
between November-December 2005 were included. Demo-
graphic and medical history data including aspirin/NSAID use,
the presence and severity-frequency of GERD and dyspepsia
symptoms were recorded, using a structured questionnaire.
GERD (heartburn, regurgitation) and dyspepsia (epigastric pain,
early satiety, postprandial fullness) diagnoses were based on
widely accepted epidemiological criteria. RESULTS: The main
reasons for patients visiting PCPs were prescription renewal
(32.9%) and consultation for upper GI symptoms (28.6%).
GERD symptoms were reported by 57.4% and dyspepsia by
67.6% of the 2878 patients during the last week before visiting
their PCP. Among patients with upper GI symptoms, GERD or
dyspepsia was reported almost equally as predominant symptom
by 34.2% and 35.6% of patients respectively, while another
4.9% reported symptoms of both diagnoses as predominant.
GERD symptoms were mild in 33%, moderate in 40% and
severe in 12% of the patients, while present for 2 days/week in
29%, 3–5 days/week in 39% and 6–7 days/week in 17% of
cases. GERD and/or dyspepsia symptoms were reported by
81.7% of users and as opposed to 62.5% of non-aspirin/NSAID
users during the last two weeks before visiting their PCP (P =
0.043). CONCLUSIONS: In patients who use primary care
health resources, GERD symptoms are highly prevalent (57%),
being present for at least 2 days/week in 85% and of moder-
ate/severe intensity in more than 50% of symptomatic patients.
Aspirin/NSAID use substantially increases prevalence of GERD
and dyspepsia symptoms.
PGI18
DISCRIMINANT VALIDITY OF THE WORK PRODUCTIVITY
AND ACTIVITY IMPAIRMENT QUESTIONNAIRE IN PATIENTS
WITH CROHN’S DISEASE
Reilly MC1, Gerlier L2, Brown M3
1Margaret Reilly Associates, Inc, New York, NY, USA, 2Keyrus
Biopharma, Levallois Perret, France, 3UCB, Slough, UK
The validity of the work productivity and activity impairment
(WPAI) questionnaire in the measurement of health-related pro-
ductivity was demonstrated in gastroesophageal reﬂux disease
and irritable bowel syndrome. The Crohn’s disease (CD) speciﬁc
WPAI (WPAI:CD) was administered in two large clinical trials
PRECiSE 1 and PRECiSE 2 that demonstrated the efﬁcacy and
tolerability of Certolizumab Pegol subcutaneous once monthly,
vs. placebo, in patients with moderate to severe CD. OBJEC-
TIVES: The objective was to compare the WPAI : CD scores of
patients categorized by baseline disease severity and health-
related quality of life (HRQoL) level, with the a priori assump-
tion that more severe health conditions are associated with
higher impairments in work productivity and daily activities.
METHODS: The 1330 randomized patients were divided into
“best” and “worst” subgroups determined by the CD Activity
